5.0 Conclusion:
In conclusion, to our knowledge, this is the first meta-analysis on the effect of ACEi/ARB in patients with COVID-19 on clinically relevant end-points. We report that patients on ACEi/ARB, who develop COVID-19, do not have an adverse outcome; more importantly, within the limitations of a meta-analysis of retrospective observational studies, there was not only a trend in reduction of hospitalization and severity of disease, but also a statistically significant reduction in death. The findings of this meta-analysis reinforce the recommendations issued by the various agencies to continue ACEi/ARB in patients with comorbidities who contract COVID-19.
Conflict of interest: None
Funding: No external source of funding.